ClinicaliQ Trial Snapshot
- A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes — Recruiting • Phase III • Diabetes / Metabolic • NCT07351058.
- Intervention being tested: Enicepatide (RO7795068), a dual GLP-1/GIP receptor agonist at multiple doses, compared with placebo for weight management and glycaemic control in patients with obesity/overweight and type 2 diabetes.
- Patient eligibility overview: Adults with obesity or overweight status who have concurrent type 2 diabetes, representing a high-risk population with significant comorbidity burden requiring integrated metabolic management.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).
Eligibility Snapshot
- : * Ability and willingness to self-administer the study drug (or receive an injection from a trained individual if visually impaired or with physical limitations) * Diagnosis of type 2 diabetes mellitus (T2DM) according to WHO classification or other locally applicable standards with HbA1c ≥6.5% to ≤10% determined by laboratory test at screening, and on stable oral therapy for at least 3 months prior to screening (if applicable). T2DM may be treated with diet/exercise alone or any oral anti-hyperglycemic medication (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1 RA-based therapy. * Body mass index (BMI) ≥27.0 kg/m^2 * History of ≥1 self-reported unsuccessful diet/exercise effort to lose body weight
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.